MKI67 and hepatoblastoma: In an experimental model (xenografted hepatoblastoma), the administration of aprepitant (80 mg/kg/day for 24 days) decreased the weight and tumor volume, the vascularized area, the serum level of tumor-specific alpha-fetoprotein (a marker of hepatoblastoma) and the number of cells expressing Ki-67 (Table 2) [85].